
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Cartesian Therapeutics Inc. (RNAC)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: RNAC (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $36.43
1 Year Target Price $36.43
4 | Strong Buy |
2 | Buy |
2 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.41% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 276.27M USD | Price to earnings Ratio - | 1Y Target Price 36.43 |
Price to earnings Ratio - | 1Y Target Price 36.43 | ||
Volume (30-day avg) 8 | Beta 0.83 | 52 Weeks Range 8.46 - 26.50 | Updated Date 08/28/2025 |
52 Weeks Range 8.46 - 26.50 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.68 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-14 | When Before Market | Estimate -0.82 | Actual -0.7724 |
Profitability
Profit Margin - | Operating Margin (TTM) -7319.13% |
Management Effectiveness
Return on Assets (TTM) -13.65% | Return on Equity (TTM) -7029.26% |
Valuation
Trailing PE - | Forward PE 25.45 | Enterprise Value 129296696 | Price to Sales(TTM) 269.27 |
Enterprise Value 129296696 | Price to Sales(TTM) 269.27 | ||
Enterprise Value to Revenue 126.02 | Enterprise Value to EBITDA -1.17 | Shares Outstanding 26002000 | Shares Floating 9390377 |
Shares Outstanding 26002000 | Shares Floating 9390377 | ||
Percent Insiders 59.85 | Percent Institutions 25.4 |
Upturn AI SWOT
Cartesian Therapeutics Inc.

Company Overview
History and Background
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering RNA cell therapy for autoimmune diseases. Founded in 2016, the company focuses on engineering cells to express RNA-encoded proteins, offering a differentiated approach from traditional gene editing or viral vector-based methods. They went public through an IPO in September 2023.
Core Business Areas
- RNA Armored Cell Therapy: Cartesian's core technology is RNA Armored Cell Therapy (rACT), which involves genetically engineering a patient's T cells with RNA to express therapeutic proteins. These engineered cells are designed to target and eliminate the underlying causes of autoimmune diseases.
Leadership and Structure
Details about Cartesian Therapeutics' leadership team and organizational structure can be found on their investor relations website. The management team is composed of individuals with experience in cell therapy, biotechnology, and pharmaceutical development.
Top Products and Market Share
Key Offerings
- Descartes-08: Descartes-08 is Cartesian's lead product candidate, an autologous rACT therapy being developed for the treatment of generalized myasthenia gravis (gMG). Clinical trial data is being generated. Competitors include Alexion (Soliris, Ultomiris) and Argenx (Vyvgart).
- Descartes-30: Descartes-30 is an autologous rACT therapy designed for the treatment of relapsed or refractory multiple myeloma (r/r MM). Clinical trial data is being generated. Competitors include Bristol Myers Squibb (Abecma), Johnson & Johnson (Carvykti), and various other MM therapies.
Market Dynamics
Industry Overview
The cell therapy market is a rapidly growing segment of the biotechnology industry, driven by advancements in genetic engineering and immunology. The market is competitive, with numerous companies developing cell-based therapies for various diseases.
Positioning
Cartesian Therapeutics is positioning itself as a leader in RNA cell therapy, differentiating itself from competitors using gene editing or viral vector-based approaches. Their rACT platform offers potential advantages in terms of safety, efficacy, and manufacturing scalability.
Total Addressable Market (TAM)
The TAM for autoimmune disease therapies and multiple myeloma therapies are substantial, representing billions of dollars annually. Cartesian's positioning to address unmet needs in these markets with rACT positions them to capture a portion of this TAM. Estimations vary but the entire cell therapy market is expected to be around 75 billion USD by 2030.
Upturn SWOT Analysis
Strengths
- Novel RNA cell therapy platform
- Potential for improved safety compared to gene editing
- Strong preclinical and early clinical data
- Experienced management team
Weaknesses
- Clinical stage company with no approved products
- High cash burn rate
- Dependence on clinical trial success
- Manufacturing complexities of cell therapies
Opportunities
- Expansion of rACT platform to other autoimmune diseases
- Partnerships with pharmaceutical companies
- Positive clinical trial results
- Advancements in manufacturing technologies
Threats
- Clinical trial failures
- Competition from other cell therapy companies
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- ALXN
- ARGX
- BMY
- JNJ
Competitive Landscape
Cartesian Therapeutics faces competition from established pharmaceutical companies and other biotechnology companies developing cell therapies. Their rACT platform offers a differentiated approach, but they need to demonstrate clinical superiority to gain market share.
Growth Trajectory and Initiatives
Historical Growth: The company's growth is primarily reflected in the advancement of its clinical pipeline and expansion of its research and development activities.
Future Projections: Future growth is dependent on the success of clinical trials, regulatory approvals, and commercialization of its rACT therapies. Analyst estimates are needed for further information. These are generally available through financial news outlets.
Recent Initiatives: Recent initiatives include progressing Descartes-08 and Descartes-30 through clinical trials, expanding the rACT platform to new disease targets, and exploring potential partnerships.
Summary
Cartesian Therapeutics is a clinical-stage biotechnology company with a novel RNA cell therapy platform targeting autoimmune diseases and multiple myeloma. The company shows promise due to its innovative approach, but is also high risk due to its dependence on clinical trial success. The firm's future hinges on positive clinical trial data and obtaining regulatory approval for its therapies. It needs to be aware of its cash burn rate, the ability to scale up its manufacturing process and the large players in its industry
Peer Comparison
Sources and Disclaimers
Data Sources:
- Cartesian Therapeutics Investor Relations
- SEC Filings (10-K, 10-Q)
- Company Press Releases
- Analyst Reports (if available)
- Industry Reports (e.g., EvaluatePharma)
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share and TAM figures are estimates and may vary based on source. The information is based on publicly available data and may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cartesian Therapeutics Inc.
Exchange NASDAQ | Headquaters Frederick, MD, United States | ||
IPO Launch date 2016-06-22 | President, CEO & Director Dr. Carsten Brunn Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 66 | |
Full time employees 66 |
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.